The Changing Face of Liver Transplantation in the United States: The Effect of HCV Antiviral Eras on Transplantation Trends and Outcomes.
Journal
Transplantation direct
ISSN: 2373-8731
Titre abrégé: Transplant Direct
Pays: United States
ID NLM: 101651609
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
02
01
2019
accepted:
04
01
2019
entrez:
19
3
2019
pubmed:
19
3
2019
medline:
19
3
2019
Statut:
epublish
Résumé
Hepatitis C virus (HCV) cirrhosis is the leading indication for liver transplantation in the United States, although nonalcoholic steatohepatitis (NASH) is on the rise. Increasingly effective HCV antivirals are available, but their association with diagnosis-specific liver transplantation rates and early graft survival is not known. The Scientific Registry of Transplant Recipients database records were retrospectively stratified by HCV antiviral era: interferon (2003-2010), protease inhibitors (2011-2013), and direct-acting antivirals (2014 to present). Kaplan-Meier, χ Liver transplants for HCV decreased (35.3% to 23.6%), whereas those for NASH and alcoholic liver disease increased (5.8% to 16.5% and 15.6% to 24.0%) with each advancing era (all Increasing effectiveness of HCV antivirals corresponds with decreased rates of liver transplantation for HCV and improved early graft survival. As the rates of liver transplant for NASH continue to increase, focus will be needed on the prevention and effective therapies for this disease.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis C virus (HCV) cirrhosis is the leading indication for liver transplantation in the United States, although nonalcoholic steatohepatitis (NASH) is on the rise. Increasingly effective HCV antivirals are available, but their association with diagnosis-specific liver transplantation rates and early graft survival is not known.
METHODS
METHODS
The Scientific Registry of Transplant Recipients database records were retrospectively stratified by HCV antiviral era: interferon (2003-2010), protease inhibitors (2011-2013), and direct-acting antivirals (2014 to present). Kaplan-Meier, χ
RESULTS
RESULTS
Liver transplants for HCV decreased (35.3% to 23.6%), whereas those for NASH and alcoholic liver disease increased (5.8% to 16.5% and 15.6% to 24.0%) with each advancing era (all
CONCLUSIONS
CONCLUSIONS
Increasing effectiveness of HCV antivirals corresponds with decreased rates of liver transplantation for HCV and improved early graft survival. As the rates of liver transplant for NASH continue to increase, focus will be needed on the prevention and effective therapies for this disease.
Identifiants
pubmed: 30882032
doi: 10.1097/TXD.0000000000000866
pii: TXD50341
pmc: PMC6411219
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e427Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Hepatology. 2000 Oct;32(4 Pt 1):852-8
pubmed: 11003634
Liver Transpl. 2001 Apr;7(4):363-73
pubmed: 11303298
Gastroenterology. 2002 Apr;122(4):889-96
pubmed: 11910340
Am J Transplant. 2006 Apr;6(4):783-90
pubmed: 16539636
Liver Transpl. 2007 Feb;13(2):197-205
pubmed: 17205563
Am J Transplant. 2008 Mar;8(3):679-87
pubmed: 18294165
Liver Transpl. 2009 Sep;15(9):1063-71
pubmed: 19718647
Liver Transpl. 2010 Apr;16(4):431-9
pubmed: 20373454
J Hepatol. 2011 Jul;55(1):207-17
pubmed: 21145865
Transplantation. 2011 Mar 27;91(6):684-9
pubmed: 21248661
Liver Transpl. 2013 Jan;19(1):78-88
pubmed: 23081888
Liver Transpl. 2014 Nov;20(11):1306-16
pubmed: 25044256
N Engl J Med. 2014 Dec 18;371(25):2375-82
pubmed: 25386767
JAMA Surg. 2015 Mar 1;150(3):252-9
pubmed: 25629390
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Am J Transplant. 2017 Feb;17(2):519-527
pubmed: 27456927
World J Gastroenterol. 2016 Oct 28;22(40):8869-8882
pubmed: 27833378
Hepatology. 2017 Mar;65(3):804-812
pubmed: 28012259
Gastroenterology. 2017 Apr;152(5):1090-1099.e1
pubmed: 28088461
Transplantation. 2017 Aug;101(8):1867-1874
pubmed: 28296807
J Clin Transl Hepatol. 2017 Jun 28;5(2):101-108
pubmed: 28660147
Hepatology. 2018 Jan;67(1):123-133
pubmed: 28802062
Clin Gastroenterol Hepatol. 2018 Mar;16(3):452-453
pubmed: 28838786
Cochrane Database Syst Rev. 2017 Sep 18;9:CD012143
pubmed: 28922704
Liver Transpl. 2018 Jun;24(6):735-743
pubmed: 29125676
Am J Transplant. 2018 Oct;18(10):2473-2482
pubmed: 29701909
Liver Int. 2018 Dec;38(12):2170-2177
pubmed: 29750389